• Cepton aims to increase active engagements and initiatives with automotive OEMs with a newly opened office located in Metro Detroit
• CPTN was added as a member to the Russell 3000(R) Index on June 27, 2022
• Cepton is a leading developer of lidar solutions for automotive (ADAS/AV), smart cities, smart spaces, and smart industrial applications
• CPTN management aims to make lidar a standard safety feature in the cars of today and the key component in the autonomous vehicles of the future

Cepton (NASDAQ: CPTN) plans to utilize its new corporate office in Metro Detroit (Troy, MI) to widen its growing engagements and initiatives with automotive original equipment manufacturers (“OEMs”) (https://ibn.fm/Bpu1g). The Silicon Valley innovator and leader specializes in high-performance Micro Motion Technology (MMT(R)) lidar solutions that enable reliable, scalable, long-range, high-resolution 3D perception for smart applications. “I’m incredibly proud that our Silicon Valley company, Cepton, has earned Detroit’s trust,” said Dr. Jun Pei, Cepton’s Co-Founder and CEO. “As we continue to expand our engagements with all of the top ten global OEMs, locating our experienced team in Detroit will serve us well. Our expanded footprint will help us reach our goal of making lidar a standard safety feature in the cars of today and the key component in the autonomous vehicles of the future.” As a result of CPTN’s rapid growth over the last year, the company was recently added to the Russell 3000(R) Index, effective June 27, 2022, as part of its annual reconstitution that roughly captures the 4,000 largest U.S. stocks as of May 6, 2022, ranked by total market capitalization. In addition, inclusion in the Russell 3000(R) Index automatically lists the company in either the large-cap Russell 1000(R) Index or small-cap Russell 2000(R) Index, along with other growth and value style indexes. “Cepton is excited to be joining the Russell 3000(R) Index as it enables us to expand awareness of our story among the investment community as we continue to execute against our milestones generating long-term stakeholder value,” said Dr. Jun Pei (https://ibn.fm/0Nb2V). “At Cepton, our design philosophy and technology enabled us to win the largest ADAS series production award to date, and inclusion in the Russell indexes is another point of validation in our ongoing journey as a public company.” Since its inception in 2016, Cepton has rapidly advanced lidar research and innovation, earning the company an award to support General Motors’ Ultra Cruise program. As a leading innovator of lidar-based solutions for automotive (ADAS/AV), smart cities, smart spaces, and smart industrial applications, Cepton aims to take its patented Micro Motion Technology (MMT(R)) mainstream to enable reliable, scalable, and cost-effective 3D perception solutions across multiple major global markets. For more information, visit the company’s website at www.Cepton.com. NOTE TO INVESTORS: The latest news and updates relating to CPTN are available in the company’s newsroom at https://ibn.fm/CPTN

• No adverse reactions were reported in any of the healthy subjects enrolled in the Cohort II Phase 1 clinical trial of PRV-002
• Company in talks with military training sites for Phase 2 and 3 clinical trials on concussed patients
• The CDC estimates that approximately 1.6 to 3.8 million sports and recreation-related concussions occur annually, for which there is no FDA-approved treatment
• The global concussion market size was valued at $6.8 billion in 2019. This value is expected to rise to $8.9 billion by 2027, growing at a CAGR of 3.6%

Odyssey Health (OTC: ODYY), a medical company focused on unique, life-saving medical products that offer clinical advantages to unmet clinical needs, has announced positive safety findings from Cohort II of their Phase 1 clinical trial. The company’s Phase 1 trial involves the administration of PRV-002, Odyssey’s novel treatment for concussions, to healthy human subjects. Findings from Cohort II have indicated that the drug is safe and well-tolerated amongst the subjects. Conducted at Nucleus Network, a leading clinical research organization, Cohort II was unblinded and evaluated by the Safety Review Committee. Cohort II was conducted using six healthy human volunteers, each receiving either one dose of PRV-002 or a placebo. These were followed up by evaluations looking for abnormal responses, which concluded no adverse effects were reported, and the drug was well tolerated. Evaluations included vital sign monitoring, EKG readings, sleep pattern, and breathing function – which were all normal. Labs indicated there were no alterations associated with the PRV-002 treatment. “PRV-002 continues to be well-tolerated as we increase the intranasal dose levels. We look forward to completing Phase I Clinical Trials and moving into a Phase II/III to determine the efficacy of PRV-002 for concussed patients,” Odyssey Health CEO Michael Redmond said (https://ibn.fm/U8T8X). “I believe that intranasal brain-targeting will be the key to its success. We are currently in discussions with military training sites for our Phase II/III clinical trials.” The Phase 1 trial is ongoing and has 40 healthy subjects administered a single ascending dose and a multi-ascending dose component. Odyssey is currently going through the process of scheduling a meeting with the FDA to present the findings from the Phase 1 trial. The company will report additional findings as they become available. “After reviewing the data from Cohort II, I have strong confidence that PRV-002 will continue to show safety for this Phase I clinical trial as an option for the treatment of concussion,” said Dallas Hack, MD, a member of the Safety Review Committee. “No abnormalities were seen, and we have unanimously approved the next cohort where the treatment dose will be doubled.” Concussions are a mild form of traumatic brain injury. They are caused by a bump, blow, or jolt to the head or body that causes rapid brain movement inside the skull. Even the slightest concussion can change the brain’s normal functions. According to the CDC, an estimated 1.6 to 3.8 million sports and recreation-related concussions occur annually in the United States (https://ibn.fm/a0Ozl). The global concussion market size was valued at $6.8 billion in 2019. Due to the rising number of accidents and sports injuries, this number is expected to grow at a CAGR of 3.6% from 2020 to 2027, resulting in a value of $8.9 billion by 2027. The leading causes of concussions in the United States include falls (52%), motor vehicle-related injury (20%), being hit by or colliding with an object (17%), and assaults (11%) (https://ibn.fm/II4pK). Odyssey’s PRV-002 is a new chemical entity, Proprietary Neurosteroid, with proven in-vivo efficacy in animal concussion models through gene amplification of anti-inflammatories, anti-oxidants, and efflux fluid channels. The administration nasally allows for the drug to reach the brain in a matter of minutes. PRV-002 is Odyssey’s solution for a medical need that currently has no FDA-approved treatment. For more information, visit the company’s website at https://odysseygi.com/. NOTE TO INVESTORS: The latest news and updates relating to ODYY are available in the company’s newsroom at https://ibn.fm/ODYY

The most crypto enabled conference in the world returns to Toronto, Canada Blockchain Futurist Conference, Canada’s largest crypto and blockchain event, combined with ETHToronto, the official Hackathon of the Blockchain Futurist Conference, is coming back to Toronto this August 8-10, 2022 for its fourth year. With only a short time until this flagship event, along with the announcement about the newly added keynote speaker Vitalik Buterin, inventor of Ethereum, the excitement among the blockchain and cryptocurrency community is rapidly growing. Here’s how the conference will be crypto and blockchain enabled for 2022 so far: The conference has introduced a multitude of digital payment methods. Untraceable has partnered with Euka Pay to accept BTC, ETH, and USDT as payment for online tickets. Untraceable has also partnered with FLEXA to set-up vendors with payment processors to accept crypto onsite including helicopter rides, food trucks, tickets, and marketplace. They are bringing back the Futurist Crypto Marketplace where Toronto based vendors will be able to sell their merchandise and learn how to accept crypto payments for their business beyond the 3 day conference.  Anyone looking to sell their merchandise and accept crypto as payment should reach out to the team. For vendors, businesses, and newbies who want to start using cryptocurrency, Futurist’s Blockchain Bootcamp is the perfect learning platform, offering education on the in-and-outs of crypto and blockchain technology. Helicopter rides, provided by FlyGTA, are one of the top activations where attendees can purchase rides around Toronto using crypto. Futurist will have 3 NFT galleries throughout the venue where attendees can bid and purchase NFTs directly on-site, this is organized in partnership with NFTGoat. NFTs will be provided by the company Ribbon, creating recognition and exclusive NFTs to all those who helped make the event possible, including volunteers, staff, and key partner organizations. For the 4th year, Untraceable brings back their event-wide gamification designed to incentivize attendees to engage within the conference. Attendees receive points for actions such as visiting exhibitor booths, attending speaking sessions, and interacting with experiences around the venue. These points can be exchanged for Untraceable tokens called UNNY. Built on the polygon network, UNNY is a real-life engagement token designed to drive real-life actions in person. Over 10 pop-ups will be activated onsite for attendees to purchase experiential activations with the conference’s native token UNNY powered by the Flexa network. This is just a snapshot of the creative activations to bring blockchain technology and cryptocurrency to real life at the 2022 Blockchain Futurist Conference. The event will be a larger-than-life experience, a future world within a conference. Gamers, programmers, hackers, startups, and more can test their technology before sending it out to the real world. Unique technologies and innovations will evolve on the floor of the Blockchain Futurist Conference. In 2019, the team successfully performed live tracking of their produce from Farm to Table at the conference – showcasing new supply chain technology, and even the conference Insurance documents are also added to the blockchain to make it immutable. Tickets are selling fast and it is time to grab your access to the conference. For those who are unable to attend the in-person event, the conference will be live in the Metaverse through Cryptovoxels. The future is almost here! See you in August! To learn more, please visit https://www.futuristconference.com. To learn more about the ETHToronto event, please visit https://www.ethtoronto.ca. Apply to showcase your NFTs for free: https://ibn.fm/ElDkF.

• The indoor air quality solution market is projected to see a CAGR of 6.30% from 2021–2025
• EPA reports that a growing body of scientific evidence has indicated that the air within homes and other buildings can be more seriously polluted than outdoor air
• Kronos air purifiers destroy the widest range of pollutants, including viruses and VOCs

With a global pandemic capturing worldwide attention and health concerns becoming increasingly important, indoor air quality is coming under increased scrutiny. A recent report projects the indoor air quality market will see significant growth in the coming years (https://ibn.fm/SgtXP), a forecast that reinforces the commitment of Kronos Advanced Technologies (OTC: KNOS) to provide the best air-purification devices and products on the market. “According to the research report ‘Indoor Air Quality Solutions Market by Product and Geography — Forecast and Analysis 2021–2025,’ the market will witness a YOY growth of 3.23% in 2021 at a CAGR of 6.30% during the forecast period,” a recent PRNews report stated. “The expanding variety of pollutants in the region is one of the primary factors driving market expansion. The number of regulations and regulatory agencies, such as the United States Environmental Protection Agency (‘EPA’), is also growing to support the market’s expansion.” In fact, the EPA recently reported that “in the last several years, a growing body of scientific evidence has indicated that the air within homes and other buildings can be more seriously polluted than the outdoor air in even the largest and most industrialized cities” (https://ibn.fm/uVwa7). Another EPA report states that “Americans, on average, spend approximately 90 percent of their time indoors, where the concentrations of some pollutants are often two to five times higher than typical outdoor concentrations. . . . Indoor concentrations of some pollutants have increased in recent decades due to such factors as energy-efficient building construction (when it lacks sufficient mechanical ventilation to ensure adequate air exchange) and increased use of synthetic building materials, furnishings, personal care products, pesticides, and household cleaners” (https://ibn.fm/0px85). These compelling reports don’t mention the threat of viruses, which have only become more of a focus with the COVID-19 global pandemic. Clearly, the need for options to clean indoor air is becoming more urgent. Enter Kronos Advanced Technologies. This innovative company is committed to offering the highest-quality air-purification devices and products available. The company’s patented technology destroys harmful particles and collects them on easy-to-wash collecting plates, reducing the risk of harmful particles entering the lungs (https://ibn.fm/8N32T). “Think of your Kronos Air Purifier as the bionic lung for your house,” the company stated, noting that Kronos purifiers destroy the widest range of pollutants, including viruses and VOCs. “It effectively filters particles down to a tiny 0.0146μm (14.6 nanometers), which is far beyond the 0.3μm (3 microns) that a traditional HEPA does. By choosing Kronos, you have a cutting-edge, high-quality home air purifier that contributes to a happier and healthier planet.” For more information, visit the company’s website at www.KronosATI.co. NOTE TO INVESTORS: The latest news and updates relating to KNOS are available in the company’s newsroom at https://ibn.fm/KNOS

• Nowigence and EquiPPP Social Impact Technologies have entered an agreement to strengthen the CSR industry in India
• The purpose is to connect donors and service organizations to improve the lives of the underprivileged in India
• Nowigence is changing the data-gathering landscape with its Pluaris(TM) platform

Nowigence (OTCQB: NOWG), the SaaS technology company behind Pluaris, a comprehensive and turnkey AI knowledge engine, is expanding its footprint and presence in India. The company announced that it has signed a memorandum of understanding with EquiPPP Social Impact Technologies Ltd. (NSE: EQUIPPP) (https://ibn.fm/lkByC). The two companies are creating a mutually beneficial strategic business alliance. According to the agreement, EquiPPP, a Hyderabad-based technology company, will support Nowigence’s business development efforts by promoting Nowigence products in India. In return, Nowigence, which is tailoring its core machine learning and natural language processing engine to develop IT and ITeSaaS (information technology enabled software as a service) products for corporate social responsibility (“CSR”) activities, will grant EquiPPP exclusive marketing rights for these CSR products in India. “We are happy to partner with EquiPPP to deliver value in the growing CSR market while benefiting society at large,” said Nowigence CEO Anoop Bhatia. “We are excited to jointly bring technology into the social programs space. Together, we hope to make a significant difference in our collective social responsibility connecting donors and service organizations to improve the lives of the underprivileged.” Nowigence is changing the data-gathering landscape with its Pluaris(TM) platform, a comprehensive, ready-to-use artificial intelligence (“AI”) offering that delivers the combined power of an intelligent reader and a smart search engine. The app reads and analyzes public and private data sources for relevant content, in real time, on any topic and for any reason. EquiPPP is engaged in IT and ITeSaaS, providing software services and offering a digital platform that supports and allows stakeholders to collaborate in implementing CSR projects. The agreement between the two companies comes at an ideal time. India is leading the way in the CSR space, requiring top Indian companies with annual revenues of more than $140 million, assets of more than $70 million, or net benefits exceeding $700,000 to spend 2% of their normal net benefits on CSR initiatives annually. The partnership dovetails nicely with this regulation, allowing EquiPPP to offer unique services ideally suited for this market. “As part of our joint business development endeavor, we shall assist the top Indian companies to not only research programs for CSR but also create a transparent, unbiased and intelligent process connecting corporations, citizens, domain experts, NGOs and philanthropists with the Indian government,” said EquiPPP CEO Mahesh Ramachandran, MD. Nowigence is an innovative software as a service (“SaaS”) company, focused on developing and bringing to market Pluaris, its comprehensive, ready-to-use artificial intelligence platform. By integrating state-of-the-art data-processing techniques in an intuitive interface at an affordable subscription price, Pluaris puts the power of data science into the hands of consumers. For more information, visit the company’s website at www.Nowigence.com. NOTE TO INVESTORS: The latest news and updates relating to NOWG are available in the company’s newsroom at https://ibn.fm/NOWG

• Flora Growth is a cannabis cultivator and distributor with a base of operations in Colombia’s fertile growing climate, capable of feeding the company’s expanding international supply chain
• Colombia has undergone a number of regulatory changes in recent years as it emerges from the shadows of years-long drug wars and embraces a growing global acceptance of cannabis products
• The South American country voted in a new presidential administration in June, and Flora Growth is applauding the president-elect’s continued openness to international cannabis trade
• Flora Growth announced significant revenue growth during its year-end financial reporting in May, and the company stated it expects another 288 to 400 percent increase in revenues during the current year

Following nationwide elections that marked a historic change in Colombia’s presidency as well as its people’s social policy aspirations, emerging cannabis brand builder Flora Growth (NASDAQ: FLGC) is expressing optimism for its market opportunities, which are based on a growing cannabis cultivation operation in the South American country. Longtime legislator Gustavo Petro, a sitting senator and previously Mayor of Bogota, was declared Colombia’s chief executive-elect June 19 after his remaining opponent in a runoff election conceded that Petro had won the majority of the vote in an orderly transfer of authority (https://ibn.fm/KBkqK). Flora Growth enjoyed explosive energy in building an international supply chain for its cannabis products under the progressive drug policy changes instituted by outgoing President Ivan Duque’s administration, and the company anticipates Petro’s approach to the market’s opportunities will further open doors for its operations. “We would like to congratulate President-Elect Gustavo Petro on his victory and we look forward to working with the new government to continue Colombia’s progressive momentum in the global cannabis industry,” Flora Growth Chairman and CEO Luis Merchan stated in a recent news release (https://ibn.fm/GpQ5t). “We are encouraged by President-Elect Petro’s stance on seeing Colombia become a leader in the legal cannabis industry and we are hopeful for progressive legislation that will allow Colombia to create a safe environment for cannabis consumption domestically — potentially leading to a recreational market in the country,” Merchan added, while observing that Colombia’s environmental and labor conditions are ideal for building successful international commerce. Petro signaled his support of the industry last year when he stated, “The possibility of legal exportation of marijuana for recreational and medicinal purposes through licenses from the national government has friends with political power in Colombia. If Colombia does not get its act together, we’re going to lose that business” (https://ibn.fm/uvgsd). Flora Growth operates a 100-hectare (about 247-acre) cultivation facility known as Cosechemos in the heart of Colombia’s green grower-friendly climate. From its cultivation, extraction and isolation operations at the city of Bucaramanga, much of its product goes to its GMP-certified processing facility for beauty, phytotherapeutic and nutraceutical products in the nation’s capital, Bogotá. The company’s license applications with Colombia’s food and drug regulatory body have included more than 20 cannabinoid-infused food and beverage products, such as juices, sparkling seltzers, gummies, chocolates, ghee butter, and healthy snack foods, that prioritize natural ingredients and value-chain sustainability (https://ibn.fm/3vI4W). “While approximately 90% of Flora’s forecasted revenue is expected to be derived outside of Colombia, we see Colombia as particularly well suited both for production of high-quality, cost-advantaged cannabis and the manufacturing of cannabinoid-derived medical formulations that can be sold domestically and internationally,” Flora’s Chief Commercial Officer Jason Warnock added in the company news release. Year-end financial results announced in May reported annual revenue of about $9 million — a “significantly higher” amount than the company reported a year earlier before Colombia’s change in its drug product laws went into effect and Flora launched its IPO on the Nasdaq Capital Market. And the company stated at the time that it expects revenues to grow another 288 to 400 percent during the current year (https://ibn.fm/TpBLQ). For more information, visit the company’s website at www.FloraGrowth.com. NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://ibn.fm/FLGC

• GMGI a standout differentiated in Benzinga’s Listmakers Series: ESports
• Golden Matrix will be launching a new P2P ESports betting platformd
• GMGI is eyeing new accretive acquisitions to extend its string of nearly 4 years of consecutive profitable quarters

Companies are usually willing to open their bank accounts for naming rights. For instance, FedEx is paying $7.5 million per year to have their name on the home field of the Washington Commanders. New tech brands are changing the game. In November 2021, Crypto.com agreed to pay $700 million to see the iconic Staples Center re-branded as Crypto.com Center for the next 20 years ($35 million/year). At the outset of Benzinga’s Listmakers Series: ESports, held June 22, 2022 featuring Golden Matrix Group (NASDAQ: GMGI), United Esports, and other heavy hitters in digital gaming, the event opened with a discussion on industry momentum that included cryptocurrency exchange FTX shelling out $210 million for the naming rights to esports organization TSM for the next 10 years. That’s nearly three times as much FTX pays each year for naming rights to the home arena for the Miami Heat of the National Basketball Association. Welcome to the digital revolution and the emergence of electronic sports into North America. Golden Matrix Group is differentiated from most companies involved in the conference insomuch that it is not an ESports team. Rather it is a leading provider of turnkey and white label gaming platforms, including Esports technology and gaming content. Golden Matrix built a name for itself with its business-to-business (“B2B”) platform, comprised of its GM-X system and the recently successful launched new GMX-Ag (aggregate) platform regarded as the industry standard, granting access to over 10,000 games from more than 25 game providers. The Las Vegas-based company is an expert in player loyalty, which allows operators to control churn and generate additional revenue from an existing player, rather than increasing expenses for new player acquisition. As of the end of the second quarter, GMGI supports over 635 unique casino operations and over 6.5 registered million players. Late in 2021, GMGI made its initial foray into the business-to-consumer (“B2C”) marketplace, with the acquisition of 80% of Ireland-based contest operator RKings. RKings owns and operates raffles for participants in Ireland and the United Kingdom. Contest prizes are frequently for big ticket items, such as automobiles, boats, exotic vacations, and more. In March, GMGI applied for a permit to operate the contests in Mexico, the next leg in international expansion for the RKings platform. With a bit of a chuckle during an interview with Benzinga’s Zunaid Suleman, Golden Matrix Group CEO Brian Goodman effectively said, “Let’s call it what it is; we’re a ‘gambling’ company, not a ‘gaming’ company.” In industry nomenclature, it is generally considered PC to not say “gambling,” even when talking about online casino games or betting on game outcomes. There are many reasons for that, including strict regulations on what is indeed a game of skill versus a game of chance and geolocation factors regarding where licenses are mandatory for operations. Goodman has been a popular figure lately, also interviewed on the latest episode the Bell2Bell podcast. There is growing choir of voices about the future of ESports gambling, but, as Goodman discusses with Suleman, there are a lot of nuances to keeping bets fair and an honest marketplace. For now, his company has built out a system for peer-to-peer (“P2P”) betting system along with some built-in games for ESports players that will be launching soon. P2P betting is legal throughout the U.S., although there are considerations for money transfers under the Wire Act that must be followed. P2P has been trumpeted for its massive potential to eliminate the “house” and creating wager unlimited wager scenarios so that bettors don’t feel like the deck is always stacked in the house’s favor. That will be a solid addition to a company that has graduated from the OTC Pink Sheets to OTCQX Best Market to NASDAQ Capital Markets in about 9 months. While many companies languished through the COVID-19 pandemic, GMGI maintained its string of profitability, which has now been extended to 15 straight quarters. From beginning of this fiscal year, the company began realizing the benefits of the RKings acquisition, which further bolstered the top and bottom lines. Revenue for the quarter ended April 30, 2022, was $8.48 million, up 221% from $2.64 million in the year prior quarter. Net income was $586,984, a gain of 359% from $127,986 in a same period a year earlier. Shareholders’ equity of GMGI of rose 37% year-over-year to $26 million from $18.93 million. The company has no debt and finished the quarter with cash and cash equivalents of $15.81 million. “We’re rolling out some new operators every week…what we’ve told the market already is that the core business will continue to grow, but we will also acquire some accretive profitable businesses in a similar line to what we do,” said Goodman. He opined that he is hopeful the company will make some acquisitions in the coming months to scale the business. “We’ve always returned value to shareholders, and we continue to grow every quarter. We don’t burn money. We’re a solid investment for people who want to get in and ride along with something that is growing,” Goodman added. For more information, visit the company’s website at www.GoldenMatrix.com. NOTE TO INVESTORS: The latest news and updates relating to GMGI are available in the company’s newsroom at https://ibn.fm/GMGI

• In 2021, Eat Well acquired Belle Pulses Ltd. Sapientia Technologies Inc. and a 51% stake at Amara Organic Foods
• These acquisitions saw a 1,082% growth in the company’s assets for the 2021 financial year and a 320% revenue growth for Amara
• With the plant-based foods market projected to be valued at $162 billion by 2030, Eat Well expects to capitalize on this growth through M&As and strategic partnerships with key players in the industry
• Eat Well is confident that with the foundation laid down so far, it is poised to achieve $100 million in revenue for 2022

At the close of the 2021 calendar year, Eat Well Investment Group (CSE: EWG) (OTC: EWGFF) (FRA: 6BC0) was regarded as “One to Watch.”  This mainly stemmed from its aggressive market expansion plans, vertical integration, and the bolstering of its leadership (https://ibn.fm/tFGDP). Over the course of the year, Eat Well proved how well its management was at sourcing, financing, and building successful companies. Together, these individuals had financed and invested in early-stage venture companies for over 25 years. The experience would allow Eat Well to acquire Belle Pulses Ltd., 100% of Sapientia Technologies Inc., and 51% shares at Amara Organic Foods. Consequently, the acquisitions would see the addition of revenue channels for Eat Well, setting the company on the road to targeting approximately $100 million in revenue for the 2022 financial year. On June 10, 2022, Eat Well released its fourth-quarter and full-year financial results for 2021, marking a 1,082% growth in assets from the previous year. Amara would post the highest revenue growth at 320% from 2020, mainly influenced by its “toddler melts” product launch across North American retail. Given its performance, Eat Well’s management expressed its optimism for 2022, citing the growth of the plant-based foods market and how well-positioned its portfolio companies are to take advantage of this growth (https://ibn.fm/UKidY). “We have laid a strong foundation within the Eat Well Group investment platform, and we are very enthusiastic about the trajectory of our portfolio,” noted Marc Aneed, Eat Well’s Director, President, and Chief Executive Officer (“CEO”). “Our portfolio companies are well positioned to capture global pulse demand and accelerate the scale of their better-for-you consumer products for years to come,” he added. It is projected that the plant-based foods market will comprise up to 7.7% of the global protein market by 2030, valued at $162 billion, up from $29.4 billion in 2020. Many analysts have even likened the food tech market to the early days of the internet in that plant-based foods represent a worldwide secular trend of steady growth and potential that will revolutionize how society functions and people experience nutrition. Through Eat Well’s aggressive yet strategic merger and acquisition (“M&A”) transactions, the company is positioning itself to take advantage of this shift in consumer preference and the growing plant-based industry. As of December 2021, Amara’s revenues had grown by over 400% since the beginning of the year, drawing media coverage from outlets such as TechCrunch and Forbes and highlighting the tremendous potential for growth for Eat Well Investment Group. Today, Eat Well supplies big companies such as Beyond Meat, Nestle, Ingredion, and General Mills, among others. As time progresses, it looks to strengthen its distribution network and its relationship with strategic partners to create value for its shareholders with its projected $100 million revenue target for 2022. For more information, visit the company’s website at www.EatWellGroup.com. NOTE TO INVESTORS: The latest news and updates relating to EWGFF are available in the company’s newsroom at https://ibn.fm/EWGFF

• The two companies signed a manufacturing operating agreement and a commercial agreement
• Lexaria sent a pre-IND meeting request letter to the US FDA and plans to file the full IND application in late 2022/early 2023
• The FDA has acknowledged Lexaria’s pre-IND request and responded with conditions prior to the target date of July 30, 2022

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has recently announced signing two agreements with BevNology LLC, the product and development arm of InterContinental Beverage Capital (“IBC”), operating its state-of-the-art lab and manufacturing facility just outside of Atlanta, Georgia. This announcement only furthers Lexaria’s leverage of the market, with the company’s patented DehydraTECH(TM) technology having already been embraced by several consumer packaged goods brands, with availability in over 7,000 stores throughout the United States and Japan, including direct-to-consumer online retail portals (https://ibn.fm/gLQzN). The manufacturing operating agreement expands the production capabilities of Lexaria’s growing list of business-to-business clientele interested in purchasing DehydraTECH-powered active ingredients for packaged-goods brands. The new, state-of-the-art processing facility built by BevNology is operational, increasing and broadening production capabilities. This facility is currently serving Lexaria’s corporate clientele, with new equipment specific to DehydraTECH already installed. The second agreement is a commercial license, empowering BevNology to offer the DehydraTECH products with active ingredients derived from hemp, including cannabidiol (“CBD”), under BevNology and partnered brands. The agreement is non-exclusive for powdered DehydraTECH formulations. For liquid formulations, the non-exclusivity is limited in the United States only, requiring certain minimum fee payments to maintain rights. Lexaria will receive royalties from BevNology for the utilization under this license, with exclusion only affecting Japan, the Republic of Korea, and the People’s Republic of China. “These agreements build on a long-standing and very successful product development consulting relationship between Lexaria and the expert scientists and personnel at BevNology.” Lexaria CEO Chris Bunka said. “BevNology’s formulation and production capabilities are class leading, and we are confident that our new relationship with our trusted partner will propel new and exciting growth opportunities for both companies.” In other recent news, Lexaria has filed its pre-IND meeting request letter with the United States Food and Drug Administration (“FDA”) to initiate communication with the FDA regarding Lexaria’s development of the company’s DehydraTECH-CBD for potential hypertension treatment. The FDA has responded to and confirmed the company’s letter, with a target date of July 30, 2022, and disclosed the conditions in which Lexaria must meet prior to the meeting. Lexaria anticipates filing the full IND application in late 2022/early 2023 (https://ibn.fm/MpKmr). “We are excited to take this important first regulatory step with the FDA for the development of our DehydraTECH-CBD for the treatment of hypertension,” stated John Docherty, President of Lexaria. “Submission of this request letter initiates formal communication with the FDA regarding our IND clinical trial plans in order to help define the critical path for clinical development and marketing approval of our potentially very significant new hypertension therapeutic.” The hypertension treatment market is valued at approximately $28 billion per year and is expected to grow as one of the world’s top health problems as a subset of a larger heart disease market (https://ibn.fm/sIjQJ). There are over 1.1 billion people in the world suffering from hypertension, with fewer than 1 in 4 having successful control over it. The potential market size increases if an affordable drug were available with few or no side effects. Some reports indicate drugs for hypertension and related conditions are among the highest-selling category of drugs in the world (https://ibn.fm/oAxXN). For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• Odyssey Health is a medical company focused on developing medical products for conditions with unmet needs, one of which is concussion
• Currently, concussions do not have an FDA-approved treatment
• Soldiers form a significant population of people who frequently experience multiple concussions throughout their career
• Concussion has only recently received greater attention as different parties seek to understand the condition and possible treatments
• Odyssey is at the forefront of this pursuit for treatment and has developed the PRV-002 drug candidate that it intends to use on the military as part of a Phase II clinical trial
• The company announced the formation of a Military Advisory Board to help in this journey

According to a study by the Business Development Bank of Canada (“BDC”), 86% of businesses with an advisory board say it has had a substantial impact on their operations. In addition, the study showed that companies with an advisory board witnessed 24% higher annual sales and 18% higher productivity than businesses without one (https://ibn.fm/K437C). Looking to tap into these favorable statistics as well as to better understand one of its important target markets, the military, Odyssey Health (OTC: ODYY), a medical company focused on unique, life-saving medical products that offer clinical advantages to conditions with unmet needs, announced the formation of a Military Advisory Board (https://ibn.fm/LJwwD). The board, which comprises associated military contacts (retired members of the U.S. armed forces who previously held leadership positions), was formed to gain experience and information that will provide crucial insights into traumatic brain injuries (“TBI”) and their effects on those who sustain TBI. “TBI in general, and mild TBI in particular, is considered a ‘silent epidemic’ because many of the acute and enduring alterations in cognitive, motor, and somatosensory functions may not be readily apparent to external observers,” an article published in the National Institutes of Health (“NIH”)’s National Library of Medicine website reads (https://ibn.fm/0P7nE). The article goes on to note that approximately 80% of all TBI cases are categorized as mild (“mTBI”). Still, these approximations are considered underestimates “because they do not account for incidents of TBI in which the person does not seek medical care.” Concussions are frequent in contact sports, with soldiers making up another significant proportion of people who frequently sustain these injuries multiple times over their careers. Latest statistics show that over 430,000 U.S. service members were diagnosed with a TBI from 2000 to 2020 (https://ibn.fm/OpnXq), with 75-83% of these cases having been categorized as mild (“mTBI”) (https://ibn.fm/PhTRQ). In addition, one analysis notes that one in six soldiers returning from deployment in Iraq met the criteria for concussion. For a long time, however, concussions did not receive the necessary urgency and attention to understand the underlying mechanisms of mild brain trauma and device potential therapeutic interventions. In fact, a New York Times article notes, many soldiers used to shrug off ailments that began following blasts – headaches, dizzy spells, numbness in their arms, dehydration, fatigue, and persistent ringing in their ears – only to later develop even more severe symptoms a few years after the explosions (https://ibn.fm/Lm1dd). But Odyssey is now spearheading efforts to understand the condition and develop treatments for concussion, which until now, does not have an FDA-approved drug. Odyssey is developing the PRV-002, a novel compound for the treatment of concussion. The drug is currently undergoing evaluations as part of a Phase I clinical trial. Upon completing the Phase 1 trial, presenting its findings to the FDA for review, and after receiving positive feedback, Odyssey intends to initiate a Phase II clinical trial in the U.S., starting with the military. This is where the Military Advisory Board will play a crucial role. The board comprises Major General USA (r) and Former Chief of Staff USSOCOM James Linder, Commanding General U.S. Army Special Operations Command (r) Francis Beaudette, Lieutenant Colonel (r) Paul Toolan, and Vice Admiral (r) Timothy Szymanski, leaders who understand firsthand the consequences of TBI on the battlefield as well as its impacts on retired and separated service members. They equally recognize the role leaders at all levels have to play to protect the comprehensive brain health of their soldiers and the underlying need to passionately and aggressively pursue treatment. “Too many service members and veterans are suffering from post-concussive events, while their families are suffering as they watch and provide care. There remains an urgent need for a concussion treatment at the point of injury that immediately treats the initial injury, speeds recovery, and potentially diminishes its long-term effects. We are obligated to pursue treatments that improve a service member’s, and their families’, well-being through their service commitment and beyond,” commented Vice Admiral (r) Timothy Szymanski (https://ibn.fm/hHCeO). For more information, visit the company’s website at https://odysseygi.com/. NOTE TO INVESTORS: The latest news and updates relating to ODYY are available in the company’s newsroom at https://ibn.fm/ODYY